Article Information
History
- July 11, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Shyam Sundar1,
- Fabiana Alves2,
- Koert Ritmeijer3,
- Margriet den Boer4,
- Colin Forsyth5,
- Bethan Hughes6,
- Clare Zamble7,
- Kirsten Carter8 and
- Gerhild Angyalosi8,*
- 1Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
- 2Drugs for Neglected Diseases Initiative, Geneva, Switzerland
- 3Médecins Sans Frontières, Amsterdam, Netherlands
- 4Médecins Sans Frontières, London, UK
- 5Drugs for Neglected Diseases Initiative, New York, NY, USA
- 6Novartis Pharmaceuticals UK Ltd, London, UK
- 7Lumanity, London, UK
- 8Novartis Pharma AG, Basel, Switzerland
- ↵*Corresponding Author:
Gerhild Angyalosi Novartis Pharma AG Basel, Switzerland gerhild.angyalosi{at}novartis.com